“The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes.
Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID). SCID is sometimes known as “bubble baby” disease, since those born with it have immune systems so weak they must live in germ-free environments.
Strimvelis is the second gene therapy to be approved in Europe, after UniQure’s Glybera, which treats a rare adult blood disorder.”
Share this entry
- Protected: The American Health Council Appoints Erin Grimes to the Occupational Therapy Board January 21, 2019
- The American Health Council appoints Ms. Kelby Kramer, R.Ph to the Healthcare Board January 15, 2019
- The American Health Council Appoints Ms. Brittney Godwin Tice to the Nursing Board January 11, 2019
- Protected: The American Health Council Appoints Dr. Adrienne Steckler to the Physician Board January 10, 2019
- Protected: The American Health Council Appoints Ms. Hannah Walker to the Industry Board January 10, 2019
- Protected: The American Health Council Welcomes New Affiliate, Dr. John Rector to the Physical Therapy Board January 10, 2019